Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B

被引:25
作者
Christophe, OD
Lenting, PJ
Cherel, G
Boon-Spijker, M
Lavergne, JM
Boertjes, R
Briquel, ME
de Goede-Bolder, A
Goudemand, J
Gaillard, S
d'Oiron, R
Meyer, D
Mertens, K
机构
[1] Hop Bicetre, INSERM, U143, F-94276 Le Kremlin Bicetre, France
[2] CLB, Dept Plasma Prot, Amsterdam, Netherlands
[3] Univ Hosp, Ctr Traitement Hemophiles, Nancy, France
[4] Sophia Childrens Univ Hosp, Rotterdam, Netherlands
[5] Hop Cardiol, Hematol Lab B, F-59037 Lille, France
[6] Hop Univ Dupuytren, Ctr Traitement Hemophiles, Limoges, France
[7] Hop Bicetre, Fac Med Paris Sud, Ctr Traitement Hemophiles, AP HP, Paris, France
[8] UIPS, Utrecht, Netherlands
关键词
D O I
10.1182/blood.V98.5.1416
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Development of inhibitory antibodies is a serious complication of treatment with repeated factor IX infusions in a minority of patients with hemophilia B. Such antibodies detected in 8 patients have been characterized. Typing studies revealed that patients' immune response toward factor IX Is highly heterogeneous and involves immunoglobulin G (IgG) antibodies, preferentially IgG1 and IgG4. The preservation of the sequence and the 3-dimensional orientation of the amino acids constituting one epitope are highly important for the assembly of an antibody-antigen complex. To localize the epitopes on the factor IX molecule, an original approach was designed using a set of factor X chimeras carrying regions of factor IX. Results showed that some patients' antibodies were directed against both the domain containing the gamma -carboxy glutamic acid residues (Gla domain) and the protease domain of factor IX. In contrast, no binding was observed to the epidermal growth factor-like domains or to the activation peptide. Functional characterization showed that the purified IgG from patients' serum Inhibited the factor VIIIa-dependent activation of factor X. Moreover, patients' IgG directed against the Gla domain inhibited the binding of factor IX to phospholipids as well as the binding of factor VIII light chain to factor IXa. These data demonstrate that Inhibitors appearing In patients with severe hemophilia B display specificity against restricted functional domains of factor IX. (C) 2001 by The American Society of Hematology.
引用
收藏
页码:1416 / 1423
页数:8
相关论文
共 43 条
[31]   LOCALIZATION OF FACTOR IXA AND FACTOR VIIIA INTERACTIVE SITES [J].
OBRIEN, LM ;
MEDVED, LV ;
FAY, PJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (45) :27087-27092
[32]   NUCLEOTIDE-SEQUENCE OF THE GENE CODING FOR HUMAN FACTOR-VII, A VITAMIN-K-DEPENDENT PROTEIN PARTICIPATING IN BLOOD-COAGULATION [J].
OHARA, PJ ;
GRANT, FJ ;
HALDEMAN, BA ;
GRAY, CL ;
INSLEY, MY ;
HAGEN, FS ;
MURRAY, MJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (15) :5158-5162
[33]   THE ROLE OF BETA-HYDROXYASPARTATE AND ADJACENT CARBOXYLATE RESIDUES IN THE 1ST EGF DOMAIN OF HUMAN FACTOR-IX [J].
REES, DJG ;
JONES, IM ;
HANDFORD, PA ;
WALTER, SJ ;
ESNOUF, MP ;
SMITH, KJ ;
BROWNLEE, GG .
EMBO JOURNAL, 1988, 7 (07) :2053-2061
[34]   EVALUATION OF 31 MOUSE MONOCLONAL-ANTIBODIES TO HUMAN-IGG EPITOPES [J].
REIMER, CB ;
PHILLIPS, DJ ;
ALOISIO, CH ;
MOORE, DD ;
GALLAND, GG ;
WELLS, TW ;
BLACK, CM ;
MCDOUGAL, JS .
HYBRIDOMA, 1984, 3 (03) :263-275
[35]   Expression, purification, and characterization of recombinant human factor X [J].
Rudolph, AE ;
Mullane, MP ;
PorcheSorbet, R ;
Miletich, JP .
PROTEIN EXPRESSION AND PURIFICATION, 1997, 10 (03) :373-378
[36]  
Saul F A, 1996, Methods Mol Biol, V66, P11
[37]  
STEL HV, 1984, BLOOD, V63, P1408
[38]  
STENFLO J, 1991, BLOOD, V78, P1637
[39]  
SULTAN Y, 1992, THROMB HAEMOSTASIS, V67, P600
[40]   EPITOPE MAPPING OF HUMAN FACTOR-IX INHIBITOR ANTIBODIES [J].
TAKAHASHI, I ;
MIZUMO, S ;
KAMIYA, T ;
TAKAMATSU, J ;
SAITO, H .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 88 (01) :166-173